WANY
LGND icon

Wealthspire Advisors (New York)’s Ligand Pharmaceuticals LGND Stock Holding History

Wealthspire Advisors (New York)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-64
Closed -$11.3K – 2070
2025
Q3 		$11.3K Buy
+64
New +$9.51K ﹤0.01% 1958

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Wealthspire Advisors (New York)'s LGND Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 64 shares — an estimated $11.3K sold.

Wealthspire Advisors (New York) first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $11.3K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 64 Ligand Pharmaceuticals shares in Q4 2025, an estimated $11.3K.
  • Wealthspire Advisors (New York) first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Ligand Pharmaceuticals position peaked at $11.3K in Q3 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.